First National Daily eMedical Newspaper of India
Nobody Reports News Better Than Us  
Editorial (Dr K K Aggarwal)                                                                                         (Dr RN Tandon)
To Read the full story on emedinexus.com, or download our Android app or iOS app
28th September, 2017
GTN : IMA TB Initiative
 
New WHO report highlights TB as a global priority for research and development
 
A recently released new report from the World Health Organization (WHO) "Antibacterial Agents in Clinical Development An analysis of the antibacterial clinical development pipeline, including tuberculosis" portrays a grim scenario by highlighting the lack of new antibiotics under development to combat the growing threat of antimicrobial resistance, which has emerged as a serious global public health concern.
 
Along with other priority antibiotic-resistant pathogens and Clostridium difficile, the report also focuses on Tuberculosis (TB) as a global priority for research and development. It draws attention to the fact that only seven new agents for TB are currently in clinical trials. Of these, four are in phase-1, and only one compound is in phase-3. This means that physicians have limited or no options for multidrug-resistant Mycobacterium tuberculosis (MDR-TB), particularly extensively drug-resistant M. tuberculosis (XDR-TB). Perhaps, in acknowledgement of this lack of therapeutic options, the Report also says, "This is especially problematic because treatment of TB infections requires a combination of at least three antibiotics. Novel treatment regimens of short duration that are assembling non-toxic drugs are desperately needed."
 
The seven agents being developed specifically for treatment of TB include pretomanid (nitroimidazole), delpazolid (oxazolidinone), SQ-109 (diamine), GSK-3036656 (Leu RS inhibitor(oxaborole)), Q-203 (imidazopyridine amide), PBTZ-169 (DprE1 inhibitor (benzothiazinone)) and OPC-167832 (DPrEq inhibitor). Only two new antibiotics for treatment of MDR-TB, bedaquiline and delamanid, have reached the market in more than seven decades.
To Read More or Comment, Click Here
Top News
Practice Updates
 
eMedi Humor
Medicolegal Corner
eMedi Quiz
1. Medial rectus and superior division of oculomotor nerve. 
2. Inferior oblique and inferior division of oculomotor nerve. 
3. Lateral rectus and abducent nerve. 
4. Superior rectus and trochlear nerve.
Lifestyle Updates
 
Inspirational Story 1: The Power of Good Words
Inspirational Story 2: Human value
Vitamin D supplementation should be started early to prevent osteoporosis
This is silent disease as it does not have any symptoms
 
New Delhi, 26 September 2017: From a research conducted recently, scientists have been able to identify what leads to bone loss in older adults. According to this, a protein called Cbf-beta plays a critical role in maintaining the bone-producing cells. When the mechanism producing this protein malfunctions, the progenitor cells stop creating bone-producing cells and instead create fat cells. It is, therefore, important to maintain this Cbf-beta to prevent human age-associated osteoporosis, which is caused due to excessive creation of fat cells.
 
Osteoporosis is condition in which the bones become weak, and even a simple fall or bump can cause a bone to break. The most common bones to break or fracture are those of the spine, hip and the wrist.
To Read More or Comment, Click Here